BVS
Bioventus IncNASDAQ
Healthcare • Medical Devices
Factor tilt: Small-Cap Blend
$10.61-0.66%
Close Nov 6, 2026
- Market cap
- $769.15M
- 1 month
- -16.4%
- 3 months
- -24.0%
- 1 year
- +43.8%
- 52-week range
- $6.53$15.26
- Dividend
- No dividends on record
- Short interest
- 9.3% of float3.2M shares · settled Oct 15, 2026 · +0.5% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Sep 30, 2026
- Revenue
- $585.64M
- Net income
- $57.3M
- Free cash flow
- $84.98M
- Book value
- $240.5M
- Total debt
- $18.75M
- P/E
- 13.4×
- Price / sales
- 1.3×
- Price / book
- 3.2×
- FCF yield
- +11.0%
- Net margin
- +9.8%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Bioventus Inc
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally.
Read more
The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
- Website
- bioventus.com
- Headquarters
- Durham, NC, United States
- Employees
- 950
- Listed
- Feb 11, 2021
- Fiscal year ends
- December
Company profile from EODHD, stored Nov 4, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Sep 2026filed Nov 2, 2026 | $142.4M | +2.7% | 68.2% | $9.7M | $6.0M |
| Jun 2026filed Aug 5, 2026 | $153.2M | +3.8% | 69.0% | $19.1M | $33.4M |
| Mar 2026filed May 6, 2026 | $132.1M | +6.6% | 67.9% | $8.9M | $3.1M |
| Dec 2025filed Mar 5, 2026 | $157.9M | +2.8% | 68.1% | $21.7M | $14.8M |
| Sep 2025filed Nov 4, 2025 | $138.7M | -0.2% | 67.0% | $12.1M | $3.2M |
| Jun 2025filed Aug 6, 2025 | $147.7M | -2.4% | 68.2% | $18.6M | $7.5M |
| Mar 2025filed May 6, 2025 | $123.9M | -4.3% | 65.8% | $5.0M | -$2.6M |
| Dec 2024filed Mar 11, 2025 | $153.6M | +13.5% | 66.8% | $8.0M | -$156.0K |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Mar 5, 2026 | $568.1M | -0.9% | 67.3% | $58.5M | $22.7M |
| Dec 2024filed Mar 11, 2025 | $573.3M | +11.9% | 67.7% | -$12.0M | -$33.5M |
| Dec 2023filed Mar 12, 2024 | $512.3M | 0.0% | 64.1% | -$81.7M | -$156.2M |
| Dec 2022filed Mar 31, 2023 | $512.1M | +18.8% | 64.6% | -$167.2M | -$158.7M |
| Dec 2021filed Mar 11, 2022 | $430.9M | +34.2% | 70.3% | $12.1M | $19.4M |
| Dec 2020filed Mar 26, 2021 | $321.2M | -5.6% | 72.7% | $21.2M | $16.4M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched BVS. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
3,177,872 shares short
+16,540 shares (+0.5%) vs Sep 30, 2026
9.3% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
3,161,332 shares short
+230,642 shares (+7.9%) vs Sep 15, 2026
9.2% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
2,930,690 shares short
+349,752 shares (+13.6%) vs Aug 31, 2026
Share of float unavailable. Published Sep 24, 2026.
Settlement Aug 31, 2026
2,580,938 shares short
+246,606 shares (+10.6%) vs Aug 14, 2026
7.7% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
2,334,332 shares short
-201,434 shares (-7.9%) vs Jul 31, 2026
6.9% of the stored float. Published Aug 25, 2026.
Settlement Jul 31, 2026
2,535,766 shares short
-193,593 shares (-7.1%) vs Jul 15, 2026
7.5% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind BVS’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if BVS is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
20 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Sep 23, 2026
Smart-money 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: unknown
No recent insider trades detected.
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 3
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
156 filers reported a long position in BVS for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
70.4%
of the 53.8M shares 13-F filers reported
Moves vs Q1 2026
7 added1 trimmed
2 unchanged
Net shares held
+5%
across the 10 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | Essex Woodlands Management, Inc. | $122.9M · 13M shares | 13M | Unchanged |
| 2 | Juniper Investment Company, LLC | $65.5M · 6.9M shares | 6.9M | Unchanged |
| 3 | Nantahala Capital Management, LLC | $56.6M · 6M shares | 6M | -2% |
| 4 | BlackRock, Inc. | $32.4M · 3.4M shares | 3.4M | +9.6% |
| 5 | ROYCE & ASSOCIATES LP | $17.3M · 1.8M shares | 1.8M | +18.9% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | $16.5M · 1.8M shares | 1.8M | +2.2% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | $12.9M · 1.4M shares | 1.4M | +16.9% |
| 8 | AMERICAN CENTURY COMPANIES INC | $12.8M · 1.4M shares | 1.4M | +118.4% |
| 9 | DIMENSIONAL FUND ADVISORS LP | $10.7M · 1.1M shares | 1.1M | +29.2% |
| 10 | STATE STREET CORP | $10.4M · 1.1M shares | 1.1M | +11.8% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of BVS file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Oct 27, 2026 | BlackRock, Inc.13G · passive · amended | 4.9%under 5% |
Get the Full Analysis for BVS
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.